The National Pharmaceutical Council Board of Directors has appointed Dr. Joshua Ofman as its new vice chairman. Read More »

AbbVie's oral poly polymerase inhibitor valiparib has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. Read More »

Kedrion Biopharma and Kamada's Biologics License Application for human anti-rabies immunoglobulin therapy has been accepted for review by the U.S. Food and Drug Administration. Read More »

Eli Lilly and Co.'s analysis of its Phase 3 baricitinib trial efficiency and safety data, as well as that of other Phase 2 trials, will be presented at the American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting, which is being held on Nov. 11-16 in Washington, D.C. Read More »

HalioDx SAS has released a report detailing the progress being made by its clinical research services. Read More »

URAC has accredited CVS Caremark's Pharmacy Adviser counseling program run by the Health Call Center and its Pharmacy Benefit Management and Drug Therapy Management. Read More »

ACADIA Pharmaceuticals' ENHANCE-1 Phase III trial involving pimavanserin has been initiated to assess the ability of pimavanserin to treat schizophrenia in patients who have had a negative response to the antipsychotic therapies currently in use. Read More »

Anthera Pharmaceuticals' Phase 2 BRIGHT-SC trial data has been selected as a poster presentation at the 2016 American Society of Nephrology’s Kidney Week Annual Meeting. Read More »

Momenta Pharmaceuticals and Mylan N.V.'s first patient in its Phase 1 study of M834 has been dosed. The trial will evaluate M834's pharmacokinetics, safety and immunogenicity. Read More »

Ajanta Pharma USA, subsidiary of Ajana Pharma Ltd., India, has released Amlodipine + Olmesartan Medoxomil Tablets in the United States. Read More »

Merck KGaA will present the data on its investigational drug for the treatment of systemic lupus erythematosus ataciept at the 2016 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting. Read More »

Aralez Pharmaceuticals Trading DAC has finalized the purchase of the rights to Toprol-XL in the U.S. and Authorized Generic from AstraZeneca. Read More »

Amgen's results of its Phase 3 coronary intravascular imaging trial, call GLAGOV, will be presented at the American Heart Association Scientific Sessions 2016. Read More »

ACADIA Pharmaceuticals' Phase II SERENE trial involving pimavanserin has begun. Read More »

The Female Health Co.'s transformational merger with Aspen Park Pharmaceuticals has been finalized with both sides agreeing to modified terms. Read More »

A licensing agreement with Norgine B.V. will give Valeant Pharmaceuticals the rights to the development and commercialization of NER1006 Powder for Oral Solution in the United States and Canada. Read More »

Valeant Pharmaceuticals and Progenics Pharmaceuticals have commercially released RELISTOR Tablets in the United States and it is now available for prescription. Read More »

ACADIA Pharmaceuticals has started its Phase II clinical trial of pimavanserin called SERENE to assess the medication’s ability to treat patients who have Alzheimer’s disease and are experiencing agitation. Read More »

Vertex Pharmaceuticals has released an update on the development of its upcoming Phase 3 program involving its investigational compound VX-661. Read More »

The Food and Drug Administration has approved Allergan's RESTASIS MULTIDOSE, its bottled version of RESTASIS, both of which are free of preservatives. Read More »